| Name | Title | Contact Details |
|---|
Leader in the manufacture of generic drugs, we produce and distribute brand name drugs and over-the-counter drugs. Based in Montreal, Canada, we have about 1 500 employees. Our products are sold in more than sixty countries. Our portfolio of 340 products cumulates 2000 different dosage strengths. We invest $ 30 million per year in research and development. We firmly believe that we must be an example in our community. We support many charities, here as elsewhere. For international humanitarian purposes, we have donated products valued at approximately $ 23.5 million over the past five years.
Curaleaf Holdings, Inc. is the leading vertically integrated multi-state cannabis operator in the United States.The company is positioned in highly populated, limited license states, and currently operates in 12 states with 44 dispensaries, 12 cultivation sites and 11 processing sites.
Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials.